SHR 1222
Alternative Names: SHR-1222Latest Information Update: 18 Jul 2023
Price :
$50 *
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action SOST protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Osteoporosis
Most Recent Events
- 18 Jul 2023 Phase-II clinical trials in Osteoporosis in China (SC) prior to July 2023 (Jiangsu HengRui Medicine pipeline, July 2023)
- 18 Jul 2022 Jiangsu HengRui Medicine completes a phase I trial in Osteoporosis in China (SC) (NCT04435158 )
- 27 Jun 2022 SHR 1222 is still in phase-I development in Osteoporosis(In volunteers) in China (SC, Injection) (Jiangsu Hengrui Pharmaceuticals pipeline, June 2022)